NeuroVive Pharmaceutical AB RSI
¿Qué es el RSI de NeuroVive Pharmaceutical AB?
El RSI de NeuroVive Pharmaceutical AB es 48.02
¿Cuál es la definición de RSI?
El índice de fortaleza relativa (RSI 14) es un indicador de impulso que compara la magnitud de las ganancias y pérdidas durante un período de tiempo específico para medir la velocidad y el cambio de los movimientos de precios de un valor.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI de compañías en Sector Miscellaneous en LSE en comparadas con NeuroVive Pharmaceutical AB
¿Qué hace NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Empresas con rsi similar a NeuroVive Pharmaceutical AB
- AND International Publishers NV tiene RSI de 48.01
- AXISCADES Engineering Technologies tiene RSI de 48.01
- Orchid Island Capital Inc tiene RSI de 48.01
- Tandy Leather Factory tiene RSI de 48.01
- Bruker Corp tiene RSI de 48.01
- Johnson Service Plc tiene RSI de 48.01
- NeuroVive Pharmaceutical AB tiene RSI de 48.02
- Douglas Dynamics Inc tiene RSI de 48.03
- E-Tech Resources tiene RSI de 48.03
- Silver One Resources tiene RSI de 48.03
- Eastern Bankshares tiene RSI de 48.03
- Sastasundar Ventures tiene RSI de 48.03
- Golden Path Acquisition tiene RSI de 48.03